Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

For lentiviral vectors intended for ex vivo cell engineering, the chain of custody for primary raw materials directly informs regulatory acceptance and clinical outcomes. Insufficient traceability of starting materials, such as plasmids and cell culture reagents, introduces significant variability and risk into the manufacturing process. A robust documentation and control system is the primary mechanism for de-risking the CMC package, ensuring lot-to-lot consistency, and supporting accelerated IND timelines.

Defining the Chain of Custody for Vector Components

The supply chain for viral vector manufacturing is complex. For sponsors on the US East Coast, navigating this complexity requires a documentation framework that can withstand intense regulatory scrutiny. The quality and safety profile of the final lentiviral vector begins with the provenance of its foundational raw materials.

Any ambiguity in the source or quality of a single plasmid or reagent can have cascading effects on the entire production run. A verifiable chain of custody serves as a fundamental risk mitigation tool, ensuring reproducibility from one manufacturing batch to the next.

The Plasmid as the Foundational Genetic Asset

The entire lentiviral vector manufacturing process is predicated on the quality of the starting plasmids. These materials function as the genetic template for the therapeutic product, making their quality a prerequisite for a successful CMC program.

Key traceability points for all plasmid lots include:

• Comprehensive vendor qualification and recurring audits.

• Independent verification of each Certificate of Analysis (CoA).

• Systematic tracking of lot-to-lot performance and purity data.

• Secure, GxP-compliant inventory management and environmental monitoring.

Mitigating Biological Risk Through Process Control

Uncontrolled variables in raw materials can introduce impurities or structural alterations to the final vector particle. These deviations can impact vector performance, such as transduction efficiency, and introduce potential safety risks. Poorly characterized biological reagents could also be a source of adventitious agents.

Meticulous control over every input material is a direct strategy to minimize the biological risks associated with the final vector product. This level of oversight ensures that the vector delivered for cell transduction is precisely what was characterized in preclinical models.

Our operating model emphasizes close scientific collaboration, providing sponsors with direct access to comprehensive expertise in all aspects of vector production and analytics. This partnership-based approach is designed to navigate complex manufacturing challenges and ensure program objectives are met with technical proficiency.

An Audit-Ready Framework for Vector Production

Within our >100,000 sq ft of laboratory and GxP-compliant space, we implement documentation systems designed for regulatory transparency. Our approach integrates material receipt, qualification, inventory control, and batch record data into a single, auditable trail.

[Video Embed: ]

This framework provides sponsors with the high-fidelity data package needed to support their regulatory filings with confidence. The programs we have supported have maintained a 100% successful IND rate since 2019, a testament to this rigorous approach, with the Franklin Biolabs brand itself launching in 2024 to carry this expertise forward. A clear and defensible traceability program is a direct contributor to achieving accelerated development timelines.